Kilitch Drugs Intrinsic Value
Kilitch Drugs intrinsic value. Kilitch Drugs (KILITCH) median intrinsic value is ₹205.71 from 9 valuation models (range ₹94–₹373), vs current price ₹233.74 — -12.0% downside (Trading Above Median Value), margin of safety -13.6%. For current market price and key ratios, visit Kilitch Drugs screener.
KILITCH Valuation Methods Summary — DCF, Graham Number & P/E
Kilitch Drugs intrinsic value across 9 models vs current price ₹233.74 — upside/downside and value range per method. Compare with KILITCH stock valuation models to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹373.12 | ₹298.50 - ₹447.74 | +59.6% | EPS: ₹16.96, Sector P/E: 22x |
| Book Value Method | asset | ₹158.29 | ₹142.46 - ₹174.12 | -32.3% | Book Value/Share: ₹79.14, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹205.71 | ₹185.14 - ₹226.28 | -12.0% | Revenue/Share: ₹102.86, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹262.86 | ₹236.57 - ₹289.15 | +12.5% | EBITDA: ₹92.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹93.50 | ₹74.80 - ₹112.20 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹108.54 | ₹97.69 - ₹119.39 | -53.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹262.03 | ₹235.83 - ₹288.23 | +12.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹274.29 | ₹246.86 - ₹301.72 | +17.3% | ROE: 21.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹158.29 | ₹142.46 - ₹174.12 | -32.3% | EPS: ₹16.96, BVPS: ₹79.14 |
KILITCH Intrinsic Value vs Market Price — All Valuation Models
Kilitch Drugs fair value range ₹94–₹373 vs current market price ₹233.74 across 9 valuation models. Read KILITCH dividend yield for the complete payout history and dividend yield track record.
KILITCH Intrinsic Value Analysis — Undervalued or Overvalued?
Kilitch Drugs median intrinsic value ₹205.71, current price ₹233.74 — Trading Above Median Value by 12.0%, margin of safety -13.6%.
What is the intrinsic value of KILITCH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Kilitch Drugs (KILITCH) is ₹205.71 (median value). With the current market price of ₹233.74, this represents a -12.0% variance from our estimated fair value.
The valuation range spans from ₹93.50 to ₹373.12, indicating ₹93.50 - ₹373.12.
Is KILITCH undervalued or overvalued?
Based on our multi-method analysis, Kilitch Drugs (KILITCH) appears to be trading above median value by approximately 12.0%.
KILITCH Financial Health — Key Ratios vs Industry Benchmarks
Kilitch Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.76 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.79x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
KILITCH Cash Flow Quality — Operating & Free Cash Flow
Kilitch Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹24 Cr | ₹-26 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹18 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-2 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹6 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |